Lv3
305 积分 2020-06-28 加入
Chemical Modification of Linkers Provides Stable Linker–Payloads for the Generation of Antibody–Drug Conjugates
2个月前
已完结
XTEN as Biological Alternative to PEGylation Allows Complete Expression of a Protease-Activatable Killin-Based Cytostatic
2个月前
已完结
Linker Architectures as Steric Auxiliaries for Altering Enzyme-Mediated Payload Release from Bioconjugates
2个月前
已完结
Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?
2个月前
已完结
Use of a Cyclic α-Alkylidene-β-Diketone as a Cleavable Linker Strategy for Antibody-Drug Conjugates
2个月前
已完结
FZ-AD005, A Novel DLL3-Targeted Antibody-drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
5个月前
已完结
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
5个月前
已完结
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
5个月前
已完结
An Unexpected Single-step Glycosylation Enables the Construction of Antibody-Biomacromolecule Conjugates as Therapeutics
6个月前
已完结
Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
8个月前
已完结
皖公网安备34019202002308
